Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study

INTRODUCTION: Epicardial fat (EF) was reported to be independently associated with cardiovascular disease regardless of obesity. We have previously reported that a sodium-glucose co-transporter-2 (SGLT2) inhibitor, luseogliflozin, reduces the EF volume (EFV) in parallel with the reduction of body we...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Fukuda, Tatsuya, Bouchi, Ryotaro, Terashima, Masahiro, Sasahara, Yuriko, Asakawa, Masahiro, Takeuchi, Takato, Nakano, Yujiro, Murakami, Masanori, Minami, Isao, Izumiyama, Hajime, Hashimoto, Koshi, Yoshimoto, Takanobu, Ogawa, Yoshihiro
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5544615/
https://ncbi.nlm.nih.gov/pubmed/28616806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-017-0279-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky